RÉSUMÉ
We report a child with acute lymphoblastic leukemia who developed primary cutaneous mucormycosis at the site of lumbar puncture during induction chemotherapy. Though high mortality rates are reported with invasive mucormycosis, prompt biopsy, early identification and antifungal therapy using a combination regime of amphotericin-B and rifampicin along with extensive surgical debridement led to complete cure of the lesions in the index case.
Sujet(s)
Amphotéricine B/usage thérapeutique , Antibactériens/usage thérapeutique , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Enfant d'âge préscolaire , Humains , Mâle , Mucormycose/induit chimiquement , Mucormycose/traitement médicamenteux , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteux , Maladies de la peau/induit chimiquement , Maladies de la peau/traitement médicamenteuxRÉSUMÉ
To determine the perception of caregivers about the disclosure of the diagnosis of HIV infection in children. Methods. Caregivers of fifty HIV-infected children were enrolled in the study after taking written informed consent. They were interviewed using a structured questionnaire. The questionnaire included information on the demographic details, questions about the disclosure status of HIV infection in children and perceptions about the disclosure of status to child. Results. Only 7 out of the 50 children (14%) were aware of their HIV status while 43/50 (86%) were unaware; as reported by their guardians/ parents. Only 6 percent children (3/50) were given factual information about the disease while 68% (34/50) were given no information. Majority of caregivers felt mid-teenage as the appropriate age for disclosing the HIV infection status and that the parents were the appropriate persons to reveal the infection status (21/50, 42%). Conclusion. There is need to develop and implement guidelines for disclosure of HIV infection status to HIV-infected children in resource limited settings.